Thymosin Alpha-1

Thymosin alpha-1 is a peptide originally isolated from thymic tissue and discussed for its immune-modulating properties. It has been studied in selected infectious, oncologic, and immune-related conditions.

Regulatory status and labeled indications, where present, differ by region and evolve over time. In many contexts it is considered an adjunctive or experimental therapy rather than a first-line standard.

Thymosin alpha-1 is thought to influence immune function through effects on T-cell maturation and activity, cytokine signaling, and innate immune responses. High-level themes include support of antiviral defenses and modulation of immune balance.

The exact mechanisms and their clinical significance vary with disease context and remain subjects of ongoing research.

Thymosin alpha-1 has been studied in settings such as chronic viral infections, certain cancers, and immune dysfunction, often as part of combination regimens.

Where approved, use is typically defined narrowly by indication and clinical criteria. In other regions, it may appear in experimental or wellness contexts that are not aligned with strong evidence or regulatory guidance.

Described adverse effects include injection-site reactions, mild flu-like symptoms, and nonspecific fatigue. As with other immune-modulating agents, there is theoretical concern about shifting immune balance in ways that may not always be beneficial.

Careful patient selection and monitoring are important, particularly in complex or immunocompromised populations.

Thymosin Alpha-1 (Tα1) modulates immune function.

This information is based on the FDA-orphan drug designation and approved international labeling.

Where it is licensed, thymosin alpha-1 is supplied as lyophilised powder with a matched diluent for subcutaneous injection. There is no approved oral, intranasal, or depot presentation, and no fixed-dose combination product.

In practice it has almost always been studied as an adjunct rather than a standalone agent — added to entecavir or peginterferon in hepatitis trials, to standard care in sepsis, to surgery in adjuvant oncology trials. That pattern is itself informative: the published benefit claims describe what it adds to another therapy, not what it does alone.

Trials of thymosin alpha-1 have examined endpoints such as viral loads, survival, and immune markers across different conditions. Results are heterogeneous and context-dependent.

Interpretation requires attention to disease setting, study design, and concurrent therapies, and cannot be fully captured by high-level summaries alone.

For deeper dives on this peptide, see:

• Thymosin Alpha-1 benefits and areas of interest
• Thymosin Alpha-1 side effects and safety context
• Thymosin Alpha-1 dosing concepts (educational)
• Thymosin Alpha-1 research and evidence overview

Is thymosin alpha-1 FDA-approved? No. It is approved in more than 35 countries for hepatitis B and C under the generic name thymalfasin (brand name Zadaxin), but it has no FDA authorisation (Goldstein & Goldstein, Expert Opin Biol Ther 2009; PMID 19392576).

Does it work for sepsis? The largest trial says no. TESTS, a multicentre double-blind phase 3 trial, gave 1.6 mg subcutaneously every 12 hours for seven days to adults with sepsis. Twenty-eight-day all-cause mortality was 23.4% (127/542) with thymosin alpha-1 versus 24.1% (132/547) with placebo — hazard ratio 0.99, 95% CI 0.77–1.27, p=0.93 (BMJ 2025; PMID 39814420).

What does the hepatitis evidence actually show? An unusual delayed pattern. Against interferon alpha in 199 patients, thymosin alpha-1 looked worse during treatment but better six months after it stopped — odds ratio 3.71 for virological response at follow-up (Antiviral Research 2008; PMID 18078676). Added to entecavir in 1,144 patients with HBV-related cirrhosis, it improved 24-week outcomes but showed no significant difference by 48 to 52 weeks (BMC Gastroenterology 2020; PMID 33076834).

Is it the same as thymosin beta-4 or TB-500? No. They share a name because both were isolated from thymic tissue extracts, and nothing else. Thymosin alpha-1 is a 28-amino-acid immune signalling peptide with regulatory approvals; thymosin beta-4 is an actin-binding peptide studied for tissue repair, approved nowhere.

Is it used for general immune support? Not in any trial. Every studied schedule is attached to a specific diagnosis — chronic hepatitis, sepsis, post-resection hepatocellular carcinoma — and given as an adjunct to another therapy. No published trial has evaluated it for immune support in healthy adults.